- Home
- VTYX vs WLAC Comparison
VTYX vs WLAC Comparison
Compare VTYX & WLAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- WLAC
- Stock Information
- Founded
- VTYX 2018
- WLAC 2024
- Country
- VTYX United States
- WLAC United States
- Employees
- VTYX N/A
- WLAC N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- WLAC
- Sector
- VTYX Health Care
- WLAC
- Exchange
- VTYX Nasdaq
- WLAC Nasdaq
- Market Cap
- VTYX 154.9M
- WLAC 172.6M
- IPO Year
- VTYX 2021
- WLAC 2024
- Fundamental
- Price
- VTYX $1.07
- WLAC $10.02
- Analyst Decision
- VTYX Buy
- WLAC
- Analyst Count
- VTYX 4
- WLAC 0
- Target Price
- VTYX $11.33
- WLAC N/A
- AVG Volume (30 Days)
- VTYX 731.3K
- WLAC 30.9K
- Earning Date
- VTYX 05-08-2025
- WLAC 01-01-0001
- Dividend Yield
- VTYX N/A
- WLAC N/A
- EPS Growth
- VTYX N/A
- WLAC N/A
- EPS
- VTYX N/A
- WLAC N/A
- Revenue
- VTYX N/A
- WLAC N/A
- Revenue This Year
- VTYX N/A
- WLAC N/A
- Revenue Next Year
- VTYX N/A
- WLAC N/A
- P/E Ratio
- VTYX N/A
- WLAC $740.58
- Revenue Growth
- VTYX N/A
- WLAC N/A
- 52 Week Low
- VTYX $1.07
- WLAC $9.80
- 52 Week High
- VTYX $5.66
- WLAC $10.19
- Technical
- Relative Strength Index (RSI)
- VTYX 23.19
- WLAC N/A
- Support Level
- VTYX $1.28
- WLAC N/A
- Resistance Level
- VTYX $1.37
- WLAC N/A
- Average True Range (ATR)
- VTYX 0.08
- WLAC 0.00
- MACD
- VTYX -0.01
- WLAC 0.00
- Stochastic Oscillator
- VTYX 0.00
- WLAC 0.00
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About WLAC Willow Lane Acquisition Corp. Class A Ordinary Shares
Willow Lane Acquisition Corp is a blank check company.